Loading stock data…
ALLR
$1.30-0.05 (-3.70%)
Market ClosedLast close May 1
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Allarity Therapeutics, Inc. in the Healthcare sector is trading at $1.30. The stock is currently 45% below its 52-week high of $2.35, remaining 6.6% above its 200-day moving average. Technical signals show neutral RSI of 63 and bearish MACD signal, explaining why ALLR maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.30
Potential Upside
5%
Whystock Fair Value$1.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-305.63%
Volume
Today's trading volume
160,295
Recent News
Allarity closes $20M financing for stenoparib advancement
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: a promissory note in the original principal amount of $10,930,000 and a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company. The financing is expected to extend
Allarity CEO says 2026 represents an ‘inflection point’
Allarity (ALLR) Therapeutics issued a letter to shareholders from the Company’s CEO, which read, in part, “As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of CEO. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t
BC-Most Active Stocks
Raytech Holding Ltd. 21,549,901 3.68